NeoNeuro is pleased to announce that they have contracted BlueDil as a supporting partner in their quest to raise seed financing.  BlueDil co-founders ,Dominique Corneillo and Sylvain Forget, bring a combined 60 years of experience in the pharmaceutical industry involving all aspects of the health science ecosystem. NeoNeuro has developed a novel platform (Aptamarkers) for the stratification of patients of Alzheimer’s disease based on blood samples. The Aptamarker platform is based on next generation sequence analysis of selected aptamer libraries applied to individual blood samples. Financing is being sought on an equity investment level as well as strategic partnerships with pharma.

For more information regarding NeoNeuro please contact, Dr. Gregory Penner at [email protected]

For more information regarding BlueDil please contact the cofounders at [email protected] or [email protected]